Abstracts tagged "cytokines"

Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 0510 • ACR Convergence 2021
Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes
Brittany Wordekemper, Nozima Aripova, Michael Duryee, Eric Daubach, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde (MDA) is produced in response to oxidative stress and is associated with inflammation and disease pathogenesis. MDA can break down and form acetaldehyde…
Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
Abstract Number: 0511 • ACR Convergence 2021
Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B
Jorge Romo-Tena¹, Jose Esparza-Lopez², Carmelo Carmona-Rivera³, Luz P blanco³, Mariana Kaplan⁴ and María de Jesús Ibarra-Sánchez², ¹INNSZ / NIAMS, Mexico City, Mexico, ²INNSZ, Mexico City, Mexico, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
Abstract Number: 1438 • ACR Convergence 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Renan Vergara¹, Alex Chen¹, Jerry Chen¹, Marianne Riley¹, Luis Blancas-Mejia¹, Christie Mortales¹, Tania Berrocal¹, Tanu Priya¹, Marsha Mason¹, Kevin Yu¹, Olga Sharapova¹, Jorgen Nelson¹, Alfredo Quijano-Rubio¹, Thomas Linsky¹, Ryan Swanson¹ and Daniel-Adriano Silva², ¹Neoleukin Therapeutics, Inc., Seattle, WA, ²Formerly of Neoleukin Therapeutics, Inc., Seattle, WA
Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
Abstract Number: 0512 • ACR Convergence 2021
Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari, Takeo Isozaki, Kuninobu Wakabayashi and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Peficitinib and filgotinib are novel Janus kinase (JAK) inhibitors developed for the treatment of rheumatoid arthritis (RA). Peficitinib inhibits all JAKs, especially JAK3. Filgotinib,…
Abstract Number: 1455 • ACR Convergence 2021
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
Jun Shimizu¹, Sueshige Wakisaka¹, Tomoko Suzuki¹ and Noboru Suzuki², ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan
Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disorder that affects cartilage of ears, nose, joints, and respiratory tract. The inflammation often spreads to eyes, cardiovascular…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 1472 • ACR Convergence 2021
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
Kazuhiro Yokota¹, Kojiro Sato², Yoshimi Aizaki³, Shinya Tanaka⁴, Miyoko Sekikawa⁴, Noritsune Kozu⁵, Yuho Kadono⁴, Hiromi Oda⁶ and Toshihide Mimura⁷, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Jichi Medical University, Tochigi, Japan, ³Saitama Medical University, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, ⁵Kozu Orthopaedic Clinic, Chiba, Japan, ⁶Department of Orthopaedic Surgery, National Hospital Organization Ibusuki Medical Center, Kagoshima, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama, Japan
Background/Purpose: We have previously reported that stimulation of mouse bone marrow–derived macrophages with a combination of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) induces…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: 0458 • ACR Convergence 2020
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Bibi Ayesha¹, Anand Kumthekar¹, Ruchi Jain², Sneha Patel³, Manish Ramesh¹, Denisa Ferastraoaru⁴, Golda Hudes⁴, Merhunisa Karagic⁴, Sheema Zafar¹, Rachel Bartash⁴, Natalia Vasquez-Canizares⁵, Elizabeth Kitsis⁶, Clement Tagoe⁷, Dawn Wahezi⁵, Tamar Rubinstein⁸ and Anna Broder³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Irvington, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Fresh Meadows, NY, ⁸Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the…
Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Yuya Fujita¹, Naoki Matsuoka¹, Makiko Furuya-Yashiro², Jumpei Temmoku², Yuki Kuroiwa³, Masaru Tanaka⁴, Tomoyuki Asano², Shuzo Sato⁵, Haruki Matsumoto², Hiroshi Watanabe², Hideko Kuzuru⁶, Hiroshi Yatsuhashi⁷, Atsushi Kawakami⁸ and Kiyoshi Migita⁹, ¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan, ²Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ³Eli Lilly Japan K.K., Tokyo, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ⁶NHO Nagasaki Medical Center, Clinical Research Center, Omura, Japan, ⁷NHO Nagasaki Medical Center, Clinical Research Center, Omura, Nagasaki, Japan, ⁸Nagasaki University Graduate School of Biomedical Sciences, Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki, Nagasaki, Japan, ⁹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…
Abstract Number: 1809 • ACR Convergence 2020
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
Fabien Vincent¹, Jannina Ong¹, Alberta Hoi², Sarah Boyd¹, Hieu Nim¹ and Eric Morand³, ¹Monash University, Clayton, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
Abstract Number: 0473 • ACR Convergence 2020
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang¹, Remy Cron², Devin Absher³, Prescott Atkinson¹, Winn Chatham¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents…
Abstract Number: 1225 • ACR Convergence 2020
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy
Yoshinobu Koyama¹, Yoshiharu Sato², Hiroshi Iijima², Moe Sakamoto³ and Toshie Higuchi³, ¹Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Division of Rheumatology, Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan
Background/Purpose: Inhibition of IL-6 signaling is one of the most established strategies for RA treatment. Tocilizumab (TCZ) is the pioneer which blocks IL-6 signaling by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].